Fig. 7

miR-196a accelerates cisplatin resistance in HNC cells via CDKN1B and ING5 downregulation. a Western blot showing p27, p21, CDK2, CDK4, Cyclin D1, and Cyclin E1 protein levels in CAL 27 and HN4 cells at 48 h after transfection with siRNA specific for CDKN1B. b Western blot showing ING5, Bcl-2, Bax, full-length Caspase 3, cleaved Caspase 3, full-length PARP, and cleaved PARP protein levels in CAL 27 and HN4 cells at 48 h after transfection with siRNA specific for ING5. c Left: western blot showing p27 and ING5 protein levels in CAL 27 and HN4 cells at 48 h after transfection with siRNAs specific for CDKN1B or ING5. Right: MTT assay showing the cisplatin response of CAL 27 and HN4 cells at 48 h after transfection, as indicated. d Left: western blot showing p27 and ING5 protein levels in CAL 27 and HN4 cells at 48 h after concurrent transfection with miR-196a and an exogenous expression vector (CDKN1B or ING5). Right: cisplatin response in CAL 27 and HN4 cells at 48 h after transfection, as indicated. e Left: western blot showing p27 and ING5 protein levels in CAL 27 and HN4 cells at 48 h after transfection with anti-miR-196a and siRNAs specific for CDKN1B or ING5. Right: cisplatin response of CAL 27 and HN4 cells at 48 h after transfection, as indicated. f Left: western blot showing p27 protein levels in CAL 27 and HN4 cells at 48 h after transfection with miR-196a and an exogenous expression vector (CDKN1B or CDKN1B 3′ UTR). Right: cisplatin resistance in CAL 27 and HN4 cells at 48 h after transfection, as indicated. g Left: western blot showing ING5 protein levels in CAL 27 and HN4 cells at 48 h after transfection with miR-196a and an exogenous expression vector (ING5 or ING5 3′ UTR). Right: cisplatin resistance in CAL 27 and HN4 cells at 48 h after transfection, as indicated. (ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001)